NCT00848965

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.

Conditions

• Rhinitis, Allergic, Perennial
• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Fluticasone propionate	Corticosteriod, with anti-inflammatory effects
DRUG	Placebo	Placebo comparator

Timeline

• Start date: 2007-10-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2009-02-23
• Last updated: 2012-09-24
• Results posted: 2012-09-24

Locations

1 site across 1 country: Austria